Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
The Allurion Program is suited for people who are unable to achieve their weight-loss goals by dieting alone or for those who do not want to, or cannot, undergo invasive surgery or endoscopy
Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Subscribe To Our Newsletter & Stay Updated